Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Cancer Prev Res (Phila). 2019 Feb 18;12(4):255–270. doi: 10.1158/1940-6207.CAPR-17-0356

Figure 4.

Figure 4.

Results from a Kaplan Meier analysis of 279 HNSCC patients from TCGA. (A). Patients with promoter methylation of PAX5 have worse outcomes than patients without PAX5 methylation (p=0.026). (B) Patients with combined somatic TP53 mutations and PAX5 promoter methylation have poorer outcomes when compared to patients with TP53 mutations, who do not have PAX5 methylation (p<0.012).